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Malignant gliomas, in particular glioblastoma (GBM), 
are incurable diseases characterised by high inter- and 
intra-tumor heterogeneity (ITH), diffuse brain 
infiltration and treatment resistance. 
Over the last fifteen years, studies at the interface 
between stem cell biology and cancer research have 
established the existence of cancer stem-like 
populations in GBM and other brain tumors (reviewed 
in [1]). These data have been accompanied by 
speculation about neural stem cells being the cell of 
origin of these malignancies. In support of this 
hypothesis, mouse models studies have repeatedly 
suggested that GBM can originate from transformed 
neural stem/precursor cells [2-4].  However, similar 
evidence in human was still missing. 
Recently, we have developed a real-time fluorescence-
guided multiple sampling (FGMS) strategy to 
investigate the extent of spatial ITH in human GBM [5]. 
This approach stems from an initial proof-of-concept 
study aimed at assessing the use of a fluorescent marker 
(5-Aminolevulinic acid, 5-ALA) to investigate the 
distribution of cancer stem-like cells (alternatively 
named tumor propagating cells) at the core and margin 
of human GBM [6]. In our recent publication [7] we 
have used FGMS to identify visible fluorescence in the 
adult sub-ventricular zone (SVZ), a germinal region of 
the human brain and, for the first time, we have started 
to reveal its role in gliomagenesis and treatment 
resistance in humans.  
Fluorescent disease was present in the SVZ of 65% of 
the GBM patients (in [7] we refer to this region as sub-
ependymal zone because we could distinguish the 
ependymal layer separating the tissue from the ventricle 
by using an intra-operative fluorescent microscope). It 
is well established that 5-ALA fluorescence is specific 
to tumor cells in GBM. Therefore we hypothesised that 
visible fluorescence in the SVZ would identify 
malignant cells. The most common genetic alterations 
of GBM identified by The Cancer Genome Atlas 
(TCGA) were present in this region of all the analysed 
patients and genomic analysis showed ITH between the 
SVZ and matched tumor mass (T), thus confirming that 
the SVZ represents a niche of malignant cells. 
Interestingly, clustering of gene expression profiles 
revealed a marked predominance of mesenchymal 
signatures in almost 80%  of the SVZ  samples  irrespec- 
 
 







tive of the subtype of the corresponding T suggesting 
that the SVZ might nurture tumor growth.  
To address the functional role of SVZ tumor cell 
populations, we characterised matched T- and SVZ-
tumor propagating cells in vitro and in vivo. We tested 
three drugs commonly used in GBM treatment: 
temozolomide (an alkylating agent that represents the 
standard of care for high grade glioma patients), 
cisplatin (an antimitotic agent) and cediranib (an 
antiangiogenic drug). Our analysis revealed three 
distinct generic patterns of drug response: a) differential 
response between T- and SVZ-cells, b) both cell 
populations responding to the drugs or c) neither of the 
two showing a good treatment response. Exposure to 
supra-maximal doses in chemo-naive patients was 
ineffective, reflecting the failure of dose-dense clinical 
studies and suggesting pre-existing resistant cell 
populations. These data shows how ITH impacts 
directly on treatment response and the emergence of 
resistant disease and confirms that the SVZ contains 
drug-resistant cells. These results have significant 
implications for treatment design and development of 
new therapeutic strategies. 
Therapeutic targeting of the SVZ will require a more 
detailed understanding of its role in gliomagenesis. We 
have previously shown that phylogenetic analysis using 
FGMS permits the discrimination of early genetic 
alterations present at all sites of GBM versus later 
alterations that are present in only part of it [5]. This 
allows the resolution of the temporal ITH that occurs 
during GBM development. Phylogenetic analysis of 8 
GBM patients revealed that the SVZ contains early 
clones in 4 out of 8 cases suggesting that this niche 
represents the “area of origin” of the tumor and also 
pointing to the neural stem/progenitor cells as the best 
candidate of malignant transformation. This is 
consistent with data from animal models [2-4]. 
However, a more complex scenario of disease evolution 
emerged in the remaining patients with the SVZ being 
characterised by late emerging clones, possibly 
originating from the malignant transformation of 
cortical progenitor cells (Fig. 1).  
Our data reveals a complicated dynamic process of 
GBM evolution that involves multiple, genetically 
diverse clonal and sub-clonal populations involving 
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efficacy of the standard line of treatments for GBM 
patients and the unrecognised involvement of the SVZ 
in gliomagenesis, we have focused our study on the 
patterns of response to treatments of SVZ- and T- 
cancer stem-like cells. The relevance of these findings 
lies in the unprecedented opportunity to improve our 
understanding of the impact of ITH on therapy response 
and GBM evolution and ultimately to the development 
of new therapeutic approaches targeting the SVZ and 
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Figure 1.   Phylogenetic analysis of human GBM  reveals  the  role of  the SVZ  in gliomagenesis.
Two different evolutionary  trajectories are observed supporting  the hypothesis  that GBM might originate
either from neural stem/progenitor cells residing in the SVZ or from cortical progenitor cells. Representative
examples of these two different scenarios are presented here (samples sp42, sp52, sp55, sp58).  
